Haisco Pharma receives IND acceptance for innovative drug HSK47977

Haisco Pharmaceutical Group (SZSE:002653) announced today that it has received an "Acceptance Notice" from the National Medical Products Administration (NMPA) for its Investigational New Drug (IND) application for HSK47977 tablets. The drug, a novel, orally administered small molecule anti-tumor agent with independent intellectual property rights, is intended for the treatment of lymphoma. The application covers both domestic production of the drug and its registration for clinical trials, with acceptance numbers CXHL2500544 and CXHL2500545 respectively. According to Haisco, there are currently no globally available therapies with the same target with published clinical data, and no such drugs have entered the clinical stage in China. Preclinical studies indicate that HSK47977 demonstrates significant proliferation inhibition of human lymphoma cell lines in vitro and effectively inhibits tumor growth in in vivo xenograft models.